Immunomic Therapeutics, Inc. Founder and CEO Bill Hearl Joins Rich Bendis for BioTalk Click to hear the interview: Bill Hearl Q&A Dr. Bill Hearl is the Founder and Chief Executive Officer ...
Our very own Dr. Heiland has been featured on BioBuzz. Click below to read the full Q&A Interview, as Dr. Heiland discusses our technology platform name change to UNITE and ...
Please read the article authored by ITI titled, “The Use and Misuse of Cancer Life Expectancy Statistics” which explores how GBM patients adjust and deal with dire life expectancy statistics. ...
May is Brain Tumor Awareness Month. In the United States, an estimated 700,000 people are living with a primary brain tumor and 79,000 more will be diagnosed this year. Gliomas ...
Congratulations to Immunomic and Astellas for winning the Best Therapeutic Vaccine award for ASP0892 (Peanut Vaccine)!
How Astellas is Working to Change Allergy Prevention through Partnership with Immunomic Therapeutics
Read how Astellas is working to address a high unmet medical need with first-of-its-kind allergy vaccine development through an innovative partnership. The following article was authored by Astellas and published on ...
Immunomic Therapeutics Welcomes Key Thought Leader in Immuno-Oncology, Dr. Drew Pardoll, to Its Scientific Advisory Board
December 13, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to welcome Drew Pardoll, MD, Ph.D., Director of ...
Congratulations to our scientific advisory board member, Dr. John Sampson, for being named to the National Academy of Medicine http://www.dukecancerinstitute.org/news/sampson-named-national-academy-medicine
A closer look at the social, cultural and political issues influencing immunization This article was produced for Immunomic Therapeutics by Scientific American Custom Media, a division separate from the magazine’s board of editors. ...
Science and health innovation do not exist in a vacuum. The cultural, social and political climate can indeed have a profound effect on funding priorities, public acceptance of new technologies ...
June 12, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc., will participate in a BioPharma Dealmakers webcast, sponsored in ...
By Colin Magowan A new interest has emerged on the CD4+ helper T cell and its role in anti-tumor responses. This renewed focus on the importance of this cell population ...